Heterozygous familial hypercholesterolemia and HIV infection: The appropriate therapeutic flow chart is still to be written?

Abstract

Get full access to this article

View all access options for this article.

References

van Zoest

van der Valk

Wit

et al.

AGEhIV Cohort Study Group. Suboptimal primary and secondary cardiovascular disease prevention in HIV-positive individuals on antiretroviral therapy. Eur J Prev Cardiol 2017; 24: 1297–1307.

Stroes

Thompson

Corsini

et al.

European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: Impact on statin therapy – European Atherosclerosis Society Consensus Panel Statement on assessment, aetiology and management. Eur Heart J 2015; 36: 1012–1022.

Pećin

Hartgers

Hovingh

et al.

Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors. Eur J Prev Cardiol 2017; 24: 1383–1401.

Nissen

Stroes

Dent-Acosta

et al.

GAUSS-3 Investigators. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: The GAUSS-3 randomized clinical trial. JAMA 2016; 315: 1580–1590.

Kohli

Ganz

et al.

HIV and hepatitis C-coinfected patients have lower low-density lipoprotein cholesterol despite higher proprotein convertase subtilisin kexin 9 (PCSK9): An apparent ‘PCSK9-lipid paradox’. J Am Heart Assoc 2016; 5: 1–9.